Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBITDA Margin (2018 - 2025)

BioNexus Gene Lab's EBITDA Margin history spans 8 years, with the latest figure at 215.88% for Q4 2025.

  • Quarterly results put EBITDA Margin at 215.88% for Q4 2025, down 17366.0% from a year ago — trailing twelve months through Dec 2025 was 34.35% (down 1883.0% YoY), and the annual figure for FY2025 was 34.35%, down 1883.0%.
  • EBITDA Margin for Q4 2025 was 215.88% at BioNexus Gene Lab, down from 27.74% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.99% in Q4 2023 to a low of 215.88% in Q4 2025.
  • The 5-year median for EBITDA Margin is 11.19% (2024), against an average of 23.02%.
  • The sharpest move saw EBITDA Margin surged 9155bps in 2024, then plummeted -17366bps in 2025.
  • Year by year, EBITDA Margin stood at 3.95% in 2021, then soared by 115bps to 8.5% in 2022, then skyrocketed by 123bps to 18.99% in 2023, then tumbled by -322bps to 42.21% in 2024, then crashed by -411bps to 215.88% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 215.88%, 27.74%, and 11.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.